1	Plasmodium vivax in haematopoietic niches: hidden and dangerous
2	
3	João Luiz Silva-Filho <sup>1,2*</sup> , Marcus V.G. Lacerda <sup>3,4</sup> , Mario Recker <sup>5</sup> , Samuel C. Wassmer <sup>6</sup> ,
4	Matthias Marti <sup>2*</sup> and Fabio T.M. Costa <sup>1*</sup>
5	
6	<sup>1</sup> Laboratório de Doenças Tropicais – Prof. Luiz Jacintho da Silva. Instituto de Biologia,
7	Universidade Estadual de Campinas, Campinas, Brazil.
8	<sup>2</sup> Wellcome Center for Integrative Parasitology, Institute of Infection, Immunity and
9	Inflammation, University of Glasgow, Glasgow, UK
10	<sup>3</sup> Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
11	<sup>4</sup> Instituto Leônidas & Maria Deane, Fiocruz Amazônia, Manaus, Brazil.
12	<sup>5</sup> Centre for Mathematics & the Environment, University of Exeter, Penryn Campus, Penryn,
13	UK.
14	<sup>6</sup> Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London
15	School of Hygiene & Tropical Medicine, London, UK.
16	*Correspondence: joao.dasilvafilho@glasgow.ac.uk (J. Silva-Filho),
17	matthias.marti@glasgow.ac.uk (M. Marti) and fabiotmc72@gmail.com (F. Costa)
18	
19	Keywords: malaria; biomass; bone marrow, spleen; reservoir; haematopoiesis.
20	
21	Abstract
22	A series of recent studies have suggested the haematopoietic niche of the bone marrow as a
23	major reservoir for parasite replication and the development of transmission stages. However
24	significant knowledge gaps remain in our understanding in the host parasite interactions,
25	pathophysiology and implications for treatment and diagnosis of such reservoir. Here, we
26	discuss the current status of this emerging research field in the context of <i>Plasmodium vivax</i> .
27	

#### Introduction

Outside of Sub-Saharan Africa, *Plasmodium vivax* dominates the malaria public health burden. In these regions it accounts for 41% of all malaria cases resulting in 35% of the global population living at risk of *P. vivax* infection [1, 2]. Even in Sub-Saharan Africa, an increase of *P. vivax* cases has been observed despite high frequency of Duffy-negative alleles [3]. In the Brazilian Amazon region, *P. vivax* is the main species causing malaria and responsible for more than 85% of all cases [1]. In general, *P. vivax* persists in areas that succeeded to eliminate *P. falciparum* by malaria control programs [4]. However, major knowledge and tool gaps remain in *P. vivax* research as the focus so far has been on *P. falciparum*.

For a long time, P. vivax research was neglected due to failure to establish an in vitro culture system and apparently low prevalence of severe cases compared to P. falciparum [5-7]. Presence of all stages in the blood circulation, and therefore assumed lack of sequestration, has contributed to the long-standing misconception that P. vivax is a benign parasite [8]. However, recent data have demonstrated that late asexual blood stage P. vivax parasites are capable of cytoadhering to endothelial host receptors [7, 9], and that they are less abundant in blood circulation than younger stages in P. vivax patients [7, 10]. Estimation of parasite biomass based on circulating biomarkers indicates existence of a predominant parasite biomass outside of circulation that is not captured by peripheral P. vivax parasitemia, in particular in patients with complicated outcomes [10]. Moreover, a series of recent histological studies in P. vivax patients and experimentally infected non-human primates (NHP) provides direct evidence for the existence of a major reservoir of P. vivax blood stage parasites, both asexual and sexual (gametocytes) in the haematopoietic niche of bone marrow and possibly spleen. These recent findings, together with more stringent diagnosis techniques of P. vivax infection suggesting a similar risk of severe disease and death as P. falciparum infection [6], strongly argue against the benign nature of P. vivax malaria, especially in patients with other comorbidities.

# P. vivax biomass in peripheral circulation: the tip of the iceberg?

*P. vivax* parasites exhibit a narrow tropism by strictly infecting young reticulocytes. In contrast, *P. falciparum* can infect normocytes even though it also prefers to infect young reticulocytes [11-14]. The restriction of *P. vivax* for young reticulocytes that are exceedingly rare in circulation (<2% of all circulating red blood cells) means parasitaemia is greatly limited by the abundance of available host cells [6, 15]. Low peripheral parasitaemia and

apparent presence of all parasite stages in the blood contradicts numerous reports of vivax malaria with severe illness and deaths due to *P. vivax* infection in all endemic regions [16-20]. It has been suggested that *P. vivax* parasites have a lower pyrogenic threshold and hence induce a stronger inflammatory response compared to other *Plasmodium* infections with similar or greater parasitaemia [15]. Indeed, the host inflammatory response and endothelial activation are greater in patients infected with *P. vivax* than with other malaria infections [19-21].

It has also been suggested that the peripheral parasitaemia represents only a fraction of the total P. vivax parasite biomass. Various indirect lines of evidence support this hypothesis. First, several reports from P. vivax patients have shown that the total parasite biomass, as define by pvLDH levels in blood, is underestimated by microscopic analysis of peripheral blood smears [6, 21]. Second, there is no clear correlation between the burden of peripheral parasitaemia and disease severity. Accordingly, a wide range of clinical syndromes occurs in P. vivax patients even with modest peripheral parasite counts, in contrast to P. falciparum-infected individuals [6, 21-31]. Third, NHP models susceptible to P. vivax infection have been very informative in inferring sequestered parasite biomass and correlations with pathogenesis [31-34]. A computational model capable to quantify the parasite biomass concealed in a tissue reservoir by measuring blood parasitaemia was designed by observing the longitudinal dynamics of P. cynomolgi parasitaemia in infected Macaca mulatta, a P. vivax simian malaria model [31]. Through the application of this model and additional observations made in vivax malaria patients it was inferred that a large fraction of parasites is withdrawn from the peripheral circulation early during blood stage infection and hidden in a reservoir, with potential role in disease pathogenesis [31, 34]. Fourth, clinical studies in P. vivax patients and in NHP models demonstrate that this hidden parasite population seemingly expands without detection and contributes to disease severity [6, 21-34], systemic inflammation [15, 21, 28] and intravascular accumulation of immune cells in pulmonary pathologies [28].

Finally, several studies have reported a biased distribution of asexual forms in blood smears of *P. vivax* patients, with higher prevalence of ring stages compared to trophozoites and schizonts in peripheral blood [7, 10]. Likewise, transcriptomic analysis from *P. vivax* blood samples demonstrated a quantitative depletion of transcripts from late asexual and immature sexual stages, or gametocytes, in the blood of *P. vivax*-infected patients [32], similar to observations with *P. falciparum* [35]. At the same time these later asexual stages display a higher adhesive capacity compared to young stages, indicating that the latter part of

the asexual *P. vivax* cycle could occur in deep tissues and outside of peripheral circulation [6, 7, 10]. Specifically, late asexual parasites are able to cytoadhere *in vitro* to endothelial receptors, such as ICAM-1, CD36 and chondroitin sulfate A (CSA), receptors expressed in cerebral, pulmonary and placental microvasculature, with a similar strength but lower frequency than red blood cells (RBCs) infected with *P. falciparum* [7, 9, 36, 37].

# Emerging evidence for a *P. vivax* reservoir in the hematopoietic niche of the bone

#### marrow

The reticulocyte population makes only 1–2% of all circulating RBCs [13, 14]. Immature reticulocytes are largely confined to the bone marrow (BM, ~0.016% of all enucleated erythroid cells in the circulation) and more cytoadhesive (higher expression of adhesion molecules such as CD49d and CD44) than circulating reticulocytes. Reticulocytes are formed from haematopoietic stem cells and released from the bone marrow niche for final maturation in the spleen [11-14, 38, 39]. *P. vivax* preferentially invades BM resident immature reticulocytes making this niche highly advantageous for the parasite. Multiple case reports have detected *P. vivax* at higher parasite biomass in the BM compared to blood, or exclusively in BM [12, 25, 40-43]. *P. vivax* infections after BM transplantation have also been reported [27, 44-46], suggesting that BM may represent a pivotal tissue reservoir in *P. vivax* infection.

A systematic analysis of *P. vivax* distribution in tissue samples from infected splenectomized *Aotus* and *Saimiri* monkeys revealed enrichment of gametocytes and schizonts in the BM and liver [32]. Together, these organs accounted for about 30% of the total parasite burden. 70% of the gametocyte load and 90% of the schizont load was accumulated in the BM and liver, suggesting that these tissues are major parasite reservoirs. Importantly, in the BM the vast majority of parasites were located in the parenchyma, where haematopoiesis takes place. Immunohistochemistry (IHC) analysis revealed that the majority of parasites detected by the constitutive marker pLDH (*Plasmodium* lactate dehydrogenase) were negative for antibodies against late sexual (PvLAP5) and asexual stages (PvAMA1) markers, indicating the enrichment of early ring stages and immature gametocytes in the BM parenchyma [32]. In agreement with these data a recent case report demonstrated enrichment of rings, schizonts and gametocytes in BM compared to blood [47]. Together, these studies suggest that the BM contributes significantly to the total *P. vivax* biomass, providing a niche for asexual growth and development of gametocyte stages (Figure 1).

These findings are in line with similar observations in *P. falciparum* and the rodent malaria parasite *P. berghei*. Autopsy case studies and analyses of biopsies and aspirates have consistently revealed a significant enrichment of *P. falciparum* immature gametocytes in the BM and spleen of infected patients [48-50]. In the BM parenchyma, gametocytes were enriched at erythroblast islands before re-entering the circulation [49]. Quantitative imaging experiments in the rodent malaria model *P. berghei* also demonstrated gametocyte development in the extravascular niche of the BM and spleen, involving selective tissue homing, transmigration across the endothelial barrier and mobile behaviour of mature gametocytes [51]. In addition, asexual parasite stages were observed in the extravascular environment both in *P. falciparum* (in human autopsies) and in *P. berghei* (in infected mice), suggesting existence of a genuine extravascular replication cycle in both *Plasmodium* species [51]. Altogether these observations establish infection of the BM haematopoietic niche as a new paradigm in *Plasmodium* biology.

## What is the role of the spleen as a parasite reservoir?

Experimental and clinical studies have demonstrated that *P. vivax* infection induces a marked splenomegaly, with incidence of splenic rupture and death higher than in other malaria infections [52-58]. In humans, the spleen contributes to the clearance of damaged and infected RBCs, generation of immunity and it changes to parasite antigens expressed on the surface of infected RBCs [54, 55]. Examinations of spleen samples from *P. vivax* patients revealed extensive remodelling, enlargement of the white pulp, increased cellularity and large numbers of intact *P. vivax*—infected reticulocytes in the red pulp [22, 54, 55]. In one case report, confocal microscopy analysis showed macrophages containing large amounts of parasite pigments, but no intact RBCs were detected in macrophages. Interestingly, intense proliferation of B cells, plasma cells and plasmablasts in extrafollicular compartments, which resembled a B-cell lymphoma phenotype was also observed [22], suggesting that alterations in the spleen are linked to acquisition of anti-parasite immunity.

Initial investigation of *P. vivax* sequestration in spleen-intact common squirrel monkeys (*Saimiri sciureus*) and night monkeys (*Aotus lemurinus lemurinus*) identified the splenic vasculature as the primary site of *P. vivax* asexual development, with a high proportion of schizont-infected RBCs [33]. The liver and BM appeared as secondary sites for trophozoite and schizont accumulation [33] while gametocytes were not analysed. Although these observations were based on organ crushes only and the organs were not perfused, a recent study in *P. vivax*-infected *Saimiri* included one spleen-intact control animal that

showed a similar pattern of parasite distribution [34]: spleen contained the highest parasite counts followed by the liver, lung and BM. In agreement with the work by Obaldia *et al.* [32], parasites were enriched in BM and liver in the splenectomised animals [34] (Figure 1). Splenectomy before infection is an important limitation in these studies, as the significant parasite load observed in BM and liver could mask a significant reservoir in the spleen. So far, no systematic autopsy case or other tissue biopsy studies of *P. vivax*-infected patients comparing the role of both spleen and BM as potential parasite reservoirs have been conducted. In *P. falciparum*, high numbers of parasites were found in spleen samples from autopsies cases [49], however it remains to be determined whether these are viable or present within macrophages. In the rodent malaria model the spleen represents the major parasite reservoir outside of circulation with significant levels of asexual and gametocyte stages [51].

In contrast to humans and primates, the adult murine spleen is haematopoietically active. However, splenic extramedullary erythropoiesis can also occur in humans during specific pathological conditions including malaria. Such mechanism has been suggested to be stimulated during vivax malaria to compensate anaemia [59], and it would further support the role of the spleen as a parasite reservoir [60-62]. In this scenario, haematopoiesis would take place in the red pulp of the spleen before the release of reticulocytes into the circulation. In addition, *P. vivax* infection may also induce a remodelling of uninfected RBCs, resulting in their arrest in the spleen. In turn, this could generate a reservoir for parasite invasion. These *P. vivax*-infected reticulocytes may remain trapped in the red pulp by interacting with contractile fibroblasts, cells that proliferate during splenic erythropoiesis and surround reticulocytes [59, 61].

#### Sub-patent infection in the hematopoietic reservoir as a source of recurrences?

The observed concealment of infected RBCs in the haematopoietic system is likely to be critical for the parasite to evade immunity and drug pressure, and this reservoir may contribute to the observed recurrence patterns in *P. vivax* infection. Proof-of-principle support of this hypothesis comes from the *P. berghei* model, which – as *P. vivax* - has a preference for young reticulocytes. Mice infected with *P. berghei* and treated with at least 10 mg/kg of artemisinin clear peripheral parasitaemia but maintain low level infection rates in BM and spleen that initiate recurrence of peripheral parasitaemia [63].

Case reports also support the hypothesis of *P. vivax* recurrence from the haematopoietic niche. For example, one report from Brazil documented a patient with persistent thrombocytopenia and an enlarged spleen who was diagnosed with chronic *P. vivax* 

malaria after discovering schizonts in BM aspirate [24]. In another case report, a patient developed vigorous vivax malaria with relatively high parasitaemia (1%) 40 days after a donor BM transplant [27]. Investigations revealed that the donor was diagnosed with malaria 11 months before BM collection, and had an asymptomatic recurrence following treatment of the first infection [27]. The uncertain origin of homologous vivax recurrences [64], case reports of *P. vivax* parasites detected only in BM aspirates without peripheral blood parasitaemia [24, 27, 40-44, 65], reports of vivax infection following sibling allogeneic BM transplants [45], and recurrence after autologous BM transplantation [46] further suggest presence of sub-patent *P. vivax* infections in the BM that can lead to recurrence. Hence BM could be an alternative source of parasite recurrence upon drug treatment, as opposed to liver relapse from quiescent hypnozoite stages. Notably, primaquine and related 8-aminoquinolines, the first line treatment against hypnozoites, are prodrugs that require activation through an enzymatic pathway that is predominant in liver and BM tissue [66].

Analysis of recurrence patterns in neurosyphilis patients who underwent malaria therapy either through inoculation by P. vivax blood stage or sporozoites provide interesting information in that regard [67]. While there is wide variation in recurrence patterns across individual patients, parasite dynamics are not significantly different during the first 2 months post infection [67], whereas only sporozoite-inoculated infections seem to exhibit recurrent parasitaemias weeks after absence of peripheral blood parasites, indicative of relapses from liver hypnozoites (Figure 2). Data from other studies performed around the same time as the malaria therapies confirm these observations. For example, a study covering around two years of observations of general paralysis in patients inoculated with P. vivax trophozoites and treated with quinine (30g, 2-4 days), revealed that 2% relapsed up to a month after end of treatment [68, 69]. In patients who survived infection after mosquito bites, 18% recurred between two to six months and 33% of these recurred more than once [68]. Another study comparing P. vivax blood stage versus sporozoite infection reported that both inoculation routes lead to 35-40% of recurrences within the first two months after termination of the primary infection, while only sporozoite infections recurred beyond that point [70]. Similar to the malaria therapy studies, a longitudinal study in rhesus monkeys infected with P. cynomolgi showed recurrence in 48% of the monkeys inoculated with trophozoites while 79% of those infected with sporozoites recurred [71]. In this study, animals who were negative by thick smear for 60 days or more underwent splenectomy: 25% of sporozoiteinfected animals relapsed up to two weeks after splenectomy, while none of the trophozoiteinfected monkeys did [71].

Taken together, comparative data from experimental infections in humans and animals indicate that both the blood stage and sporozoite infection routes can exhibit similar recurrence patterns, at least during the first 2 months post infection and following (subcurative) drug treatment. On the other hand, the limited data available indicates that hypnozoite relapse have a much greater contribution during later phases of infection, which together suggests that the BM reservoir and liver hypnozoites are distinct but synergistic strategies by which the parasite prolongs infection and thus enhances its transmission success.

### What are the implications of *P. vivax* development in the BM for the host?

Parasite infection in the haematopoietic niche has implications for malaria pathogenesis, diagnosis and treatment. The BM parenchyma is a specialized and complex microenvironment that provides a set of molecular, structural and physical cues to regulate hematopoietic stem and progenitor cell (HSPC) production [72]. Haematopoiesis is a dynamic biological process that can also be responsive and shaped by pathogens during infection. HSPCs are capable of responding to pathogens by directly sensing pathogen-associated molecule patterns (PAMPs) through their respective pathogen-recognition receptors (PRRs). They also express a broad range of cytokines/chemokines receptors, which allows them to detect pro-inflammatory signals (DAMPs).

Recent studies investigating the impact of parasite infection in the BM have focused on potential changes in erythropoiesis to understand the pathophysiology of vivax malaria anaemia [47, 73]. These changes include altered levels of miRNA transcripts [48] and impaired activity of transcription factors, such as GATA1/GATA2 [74, 75], regulating erythropoiesis. GATA1/GATA2 changes are mediated by intermediate and non-classical monocytes and activation of IFN type I and II signalling pathways in the BM [74]. Similarly, IFN-γ is implicated in malarial anaemia in rodent malaria models and can directly cause apoptosis of erythroid progenitors in vitro [76]. It has also been suggested that inflammatory cytokines produced by macrophages and monocytes in the BM in response to parasite byproducts promote the dyserythropoiesis observed during malarial anaemia [77]. In P. vivaxinfected patients lymphopenia and thrombocytopenia are common clinical signs of infection, while myeloid cell count (e.g., monocytes and neutrophils) often remain unchanged in the peripheral blood [6, 15, 21, 24, 73, 78-81]. Although the level of cytokines implicated in the expansion of the megakaryocyte lineage and myelopoiesis in the BM remain to be determined, these molecules (e.g., IL-1α, IL-1β, IL-6, IL-8, TNF-α, IFN-γ, thrombopoietin [TPO] and G-CSF) are increased in the plasma of P. vivax patients [15, 21, 24, 73, 78, 82-84].

Increased cytokine levels inducing myeloid-biased HSC differentiation while reducing lymphopoiesis could explain the normal counts of myeloid cells and decrease of lymphocytes in the circulation in P. vivax patients [21, 24, 73, 78]. Indeed, less differentiated neutrophils (band cells) in peripheral blood are increased in P. vivax patients during acute infection, possibly as a result of rapid neutrophil production and/or their premature release from the BM [78, 79]. Likewise, elevated levels of cytokines inducing megakaryocyte differentiation indicates that the BM mounts a response to compensate reduced platelet counts in peripheral blood. Analysis of a BM biopsy from a patient with chronic vivax malaria revealed hyperplasia of myeloid and megakaryocytic cells [24], and a similar phenotype has been described in P. cynomolgi-infected monkeys [74]. In the rodent malaria model P. chabaudi it was demonstrated that IFN-y signalling in hematopoietic progenitors induces myeloid-biased differentiation and myeloid cell numbers, which appeared to be associated with parasite clearance [85]. A similar mechanism was also observed in the P. berghei rodent malaria model [86]. The analysis of P. cynomolgi infection in Rhesus macaques also demonstrated transcriptomic changes in the BM including upregulation of IFN-y and IL-27, as well as pathways related to pathogen recognition, such as TLRs, NOD-like receptors and RIG-1/MDA5 [74]. Of note, reticulocytes express parasite antigens via human leukocyte antigen class I (HLA-1), which are recognized by antigen-specific CD8<sup>+</sup> T cells, resulting in the formation of immunological synapses and killing of the *P. vivax*–infected reticulocytes [87].

Collectively, these observations suggest that *P. vivax* antigens can be presented and induce immune responses in the extravascular niches of the BM. Resident cells including haematopoietic progenitor/stem cell (HPSCs) could adapt to these signals through proliferation, mobilization from the BM and skewing toward the myeloid lineage, at the expense of lymphopoiesis [82-84] (Figure 3, Key Figure). However, this infection-induced adaptation toward enhanced myelopoiesis might also perpetuate inflammation in chronic or repeated infections by generating a feed-forward loop between myeloid-biased HSPCs and the inflammatory response. Indeed, chronic HSPC activation by infection and/or inflammatory stimuli causes impairment of function and exhaustion, alters global patterns of gene expression skewing hematopoietic potential and further perpetuates inflammation, which leads to BM remodelling and potentially myelodysplastic syndromes [84]. It will be important to investigate acute and long-term impacts of *P. vivax* infection in the BM, in particular in patients continuously exposed to the parasite.

## **Concluding remarks**

Recent studies have demonstrated that the haematopoietic niche represents a major reservoir for *P. vivax* that is subject to significant changes during infection. These observations raise a series of questions with regards to parasite biology (see Outstanding questions). In addition, the host-parasite interactions established in the different reservoirs and their clinical implications represent key knowledge gaps. Because *P. vivax* develops/accumulates in the BM parenchyma, its antigens and parasite-induced cytokines can potentially be sensed by HSPCs, MSCs, ECs and mature immune cells in the BM parenchyma and shape its function. This raises questions about the underlying host-parasite interactions in hematopoietic stem cell niche environments (see Outstanding questions). Understanding the acute and long-term effects of the hidden parasite biomass in haematopoietic reservoirs is relevant to the study of acute and chronic *P. vivax* infection. In addition, NHP models and human cohort studies (autopsies, BM and/or spleen aspirates – see Box 1) will be of great value to further evaluate the importance of the haematopoietic reservoirs for *P. vivax* survival, recurrence, transmission and pathogenesis.

## **Acknowledgements:**

S.C.W. is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (award numbers U19AI089676 and R21AI142472), and the UK Medical Research Council (award number MR/S009450/1). M.M. is supported by a Wolfson Merit Award from the Royal Society. J.LS.F. is supported by the Sao Paulo Research Foundation (FAPESP grant 2019/01578-2 and 2016/12855-9) and F.T.M.C is supported by the Sao Paulo Research Foundation (FAPESP grant 2017/18611-7). M.V.G.L. and F.T.M.C. are CNPq research fellows. We would like to thank Ana Carolina A. V. Kayano (carolavk@gmail.com) for the excellent work in designing the Figure 3. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

#### 325 References

- 1. WHO, World Malaria Reports, in: Organization, W.H. (Ed.) 2017.
- 2. Guerra, C.A. et al. (2010) The international limits and population at risk of Plasmodium
- vivax transmission in 2009. PLoS Negl Trop Dis 4 (8), e774.
- 3. Zimmerman, P.A. (2017) Infection in Duffy-Negative People in Africa. Am J Trop Med
- 330 Hyg 97 (3), 636-638.
- 4. Hsiang, M.S. et al. (2013) Mass drug administration for the control and elimination of
- Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J 12,
- 333 383
- 5. Guerra, C.A. et al. (2006) Mapping the global extent of malaria in 2005. Trends Parasitol
- 335 22 (8), 353-8.
- 336 6. Baird, J.K. (2013) Evidence and implications of mortality associated with acute
- Plasmodium vivax malaria. Clin Microbiol Rev 26 (1), 36-57.
- 7. Totino, P.R. and Lopes, S.C. (2017) Insights into the Cytoadherence Phenomenon of. Front
- 339 Immunol 8, 1148.
- 8. Wassmer, S.C. and Grau, G.E. (2017) Severe malaria: what's new on the pathogenesis
- 341 front? Int J Parasitol 47 (2-3), 145-152.
- 9. Carvalho, B.O. et al. (2010) On the cytoadhesion of Plasmodium vivax-infected
- 343 erythrocytes. J Infect Dis 202 (4), 638-47.
- 10. Lopes, S.C. et al. (2014) Paucity of Plasmodium vivax mature schizonts in peripheral
- blood is associated with their increased cytoadhesive potential. J Infect Dis 209 (9), 1403-7.
- 346 11. Malleret, B. et al. (2015) Plasmodium vivax: restricted tropism and rapid remodeling of
- 347 CD71-positive reticulocytes. Blood 125 (8), 1314-24.
- 12. Ru, Y.X. et al. (2009) Invasion of erythroblasts by Pasmodium vivax: A new mechanism
- contributing to malarial anemia. Ultrastruct Pathol 33 (5), 236-42.
- 13. Kanjee, U. et al. (2018) Molecular and cellular interactions defining the tropism of
- Plasmodium vivax for reticulocytes. Curr Opin Microbiol 46, 109-115.
- 352 14. Ovchynnikova, E. et al. (2017) DARC extracellular domain remodeling in maturating
- 353 reticulocytes explains. Blood 130 (12), 1441-1444.
- 15. Anstey, N.M. et al. (2009) The pathophysiology of vivax malaria. Trends Parasitol 25 (5),
- 355 220-7.
- 356 16. Val, F. et al. (2017) Respiratory Complications of. Am J Trop Med Hyg 97 (3), 733-743.
- 17. Naing, C. et al. (2014) Is Plasmodium vivax malaria a severe malaria?: a systematic
- review and meta-analysis. PLoS Negl Trop Dis 8 (8), e3071.
- 18. Poespoprodjo, J.R. et al. (2009) Vivax malaria: a major cause of morbidity in early
- 360 infancy. Clin Infect Dis 48 (12), 1704-12.
- 19. Kochar, D.K. et al. (2010) Thrombocytopenia in Plasmodium falciparum, Plasmodium
- vivax and mixed infection malaria: a study from Bikaner (Northwestern India). Platelets 21
- 363 (8), 623-7.
- 20. Yeo, T.W. et al. (2010) Greater endothelial activation, Weibel-Palade body release and
- host inflammatory response to Plasmodium vivax, compared with Plasmodium falciparum: a
- prospective study in Papua, Indonesia. J Infect Dis 202 (1), 109-12.
- 21. Barber, B.E. et al. (2015) Parasite biomass-related inflammation, endothelial activation,
- 368 microvascular dysfunction and disease severity in vivax malaria. PLoS Pathog 11 (1),
- 369 e1004558.
- 22. Machado Siqueira, A. et al. (2012) Spleen rupture in a case of untreated Plasmodium
- vivax infection. PLoS Negl Trop Dis 6 (12), e1934.
- 372 23. Lacerda, M.V. et al. (2012) Postmortem characterization of patients with clinical
- diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? Clin Infect Dis
- 374 55 (8), e67-74.

- 24. Lacerda, M.V. et al. (2008) Chronic Plasmodium vivax infection in a patient with
- splenomegaly and severe thrombocytopenia. Rev Soc Bras Med Trop 41 (5), 522-3.
- 377 25. Yoeli, M. (1948) Non-pigmented malaria parasites in the bone marrow from a mixed
- infection of leishmania and plasmodium vivax. Trans R Soc Trop Med Hyg 42 (1), 99.
- 26. Imirzalioglu, C. et al. (2006) Diagnosis of mixed Plasmodium malariae and P. vivax
- infection in a development aid volunteer by examination of bone-marrow specimens by real-
- 381 time PCR. J Clin Microbiol 44 (6), 2307-10.
- 382 27. O'Donnell, J. et al. (1998) Donor-derived Plasmodium vivax infection following
- volunteer unrelated bone marrow transplantation. Bone Marrow Transplant 21 (3), 313-4.
- 384 28. Anstey, N.M. et al. (2007) Lung injury in vivax malaria: pathophysiological evidence for
- pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect
- 386 Dis 195 (4), 589-96.
- 387 29. Nurleila, S. et al. (2012) Serious and fatal illness associated with falciparum and vivax
- 388 malaria among patients admitted to hospital at West Sumba in eastern Indonesia. Am J Trop
- 389 Med Hyg 87 (1), 41-49.
- 390 30. Lança, E.F. et al. (2012) Risk factors and characterization of Plasmodium vivax-
- associated admissions to pediatric intensive care units in the Brazilian Amazon. PLoS One 7
- 392 (4), e35406.
- 393 31. Fonseca, L.L. et al. (2017) A model of Plasmodium vivax concealment based on
- Plasmodium cynomolgi infections in Macaca mulatta. Malar J 16 (1), 375.
- 395 32. Obaldia, N. et al. (2018) Bone Marrow Is a Major Parasite Reservoir in Plasmodium
- 396 vivax Infection. MBio 9 (3).
- 397 33. Fremount, H.N. and Rossan, R.N. (1990) Anatomical distribution of developing
- 398 trophozoites and schizonts of Plasmodium vivax in Aotus lemurinus lemurinus and Saimiri
- 399 sciureus. J Parasitol 76 (3), 428-30.
- 400 34. Peterson, M.S. et al. (2019) Parasite Load Is Associated With Histopathology in Saimiri
- 401 boliviensis With Findings Comparable to P vivax Pathogenesis in Humans. Open Forum
- 402 Infect Dis 6 (3), of z021.
- 403 35. Pelle, K.G. et al. (2015) Transcriptional profiling defines dynamics of parasite tissue
- sequestration during malaria infection. Genome Med 7 (1), 19.
- 405 36. De las Salas, B. et al. (2013) Adherence to human lung microvascular endothelial cells
- 406 (HMVEC-L) of Plasmodium vivax isolates from Colombia. Malar J 12, 347.
- 407 37. Chotivanich, K. et al. (2012) Plasmodium vivax adherence to placental
- 408 glycosaminoglycans. PLoS One 7 (4), e34509.
- 38. Klei, T.R. et al. (2017) From the Cradle to the Grave: The Role of Macrophages in
- Erythropoiesis and Erythrophagocytosis. Front Immunol 8, 73.
- 39. Rhodes, M.M. et al. (2016) Stress reticulocytes lose transferrin receptors by an extrinsic
- process involving spleen and macrophages. Am J Hematol 91 (9), 875-82.
- 40. A, S. and RL, L., Sternal puncture, with special reference to its application in tropical
- diseases in South China., J Trop Med Hyg 1938, pp. 341-342.
- 41. GJ., A., Sternal puncture in the diagnosis of malaria., Lancet., 1943, pp. 466-468.
- 42. Rumball CA, P.-S.B., Nancekievill L., Sternal puncture in the diagnosis of malaria., 1943,
- 417 pp. 468-469.
- 43. LEVINE, H.D. (1946) Medical experiences with American troops in the Pacific; with
- remarks on the diagnostic value of sternal puncture in malaria and on the innocuousness of
- hookworm infection. N Engl J Med 235 (26), 933-8.
- 421 44. Wickramasinghe, S.N. et al. (1989) Dyserythropoiesis and ineffective erythropoiesis in
- 422 Plasmodium vivax malaria. Br J Haematol 72 (1), 91-9.
- 423 45. Raina, V. et al. (1998) Plasmodium vivax causing pancytopenia after allogeneic blood
- stem cell transplantation in CML. Bone Marrow Transplant 22 (2), 205-6.

- 425 46. Salutari, P. et al. (1996) Plasmodium vivax malaria after autologous bone marrow
- transplantation: an unusual complication. Bone Marrow Transplant 18 (4), 805-6.
- 47. Baro, B. et al. (2017) Plasmodium vivax gametocytes in the bone marrow of an acute
- malaria patient and changes in the erythroid miRNA profile. PLoS Negl Trop Dis 11 (4),
- 429 e0005365.
- 48. Bach, O. et al. (2005) Falciparum malaria after splenectomy: a prospective controlled
- study of 33 previously splenectomized Malawian adults. Trans R Soc Trop Med Hyg 99 (11),
- 432 861-7.
- 433 49. Joice, R. et al. (2014) Plasmodium falciparum transmission stages accumulate in the
- human bone marrow. Sci Transl Med 6 (244), 244re5.
- 435 50. Safeukui, I. et al. (2008) Retention of Plasmodium falciparum ring-infected erythrocytes
- in the slow, open microcirculation of the human spleen. Blood 112 (6), 2520-8.
- 437 51. De Niz, M. et al. (2018) Plasmodium gametocytes display homing and vascular
- transmigration in the host bone marrow. Sci Adv 4 (5), eaat3775.
- 439 52. Zingman, B.S. and Viner, B.L. (1993) Splenic complications in malaria: case report and
- 440 review. Clin Infect Dis 16 (2), 223-32.
- 53. Schmidt, L.H. (1978) Plasmodium falciparum and Plasmodium vivax infections in the
- owl monkey (Aotus trivirgatus). I. The courses of untreated infections. Am J Trop Med Hyg
- 443 27 (4), 671-702.
- 444 54. Imbert, P. et al. (2010) Left upper quadrant abdominal pain in malaria: suspect
- pathological splenic rupture first. Trans R Soc Trop Med Hyg 104 (9), 628.
- 55. LUBITZ, J.M. (1949) Pathology of the ruptured spleen in acute vivax malaria. Blood 4
- 447 (10), 1168-76.
- 56. Imbert, P. et al. (2009) Pathological rupture of the spleen in malaria: analysis of 55 cases
- 449 (1958-2008). Travel Med Infect Dis 7 (3), 147-59.
- 450 57. Boone, K.E. and Watters, D.A. (1995) The incidence of malaria after splenectomy in
- 451 Papua New Guinea. BMJ 311 (7015), 1273.
- 452 58. Grobusch, M.P. et al. (2003) Severe malaria in a splenectomised Gabonese woman. Wien
- 453 Klin Wochenschr 115 (1-2), 63-5.
- 454 59. del Portillo, H.A. et al. (2004) Variant genes and the spleen in Plasmodium vivax malaria.
- 455 Int J Parasitol 34 (13-14), 1547-54.
- 456 60. Beguin, Y. et al. (1989) Ferrokinetic study of splenic erythropoiesis: relationships among
- 457 clinical diagnosis, myelofibrosis, splenomegaly, and extramedullary erythropoiesis. Am J
- 458 Hematol 32 (2), 123-8.
- 459 61. Bowdler, A.J. (2002) The complete spleen: structure, function, and clinical disorders,
- 460 2nd ed. edn., Humana Press.
- 62. Palitzsch, K.D. et al. (1987) Splenic haematopoiesis in patients with cirrhosis of the liver.
- Virchows Arch A Pathol Anat Histopathol 411 (2), 179-83.
- 463 63. Lee, R.S. et al. (2018) A cryptic cycle in haematopoietic niches promotes initiation of
- 464 malaria transmission and evasion of chemotherapy. Nat Commun 9 (1), 1689.
- 64. Imwong, M. et al. (2012) The first Plasmodium vivax relapses of life are usually
- genetically homologous. J Infect Dis 205 (4), 680-3.
- 467 65. Liu, X. et al. (2012) A case of congenital plasmodium vivax malaria from a temperate
- 468 region in Central China. Malar J 11, 182.
- 66. Camarda, G. et al. (2019) Antimalarial activity of primaquine operates via a two-step
- biochemical relay. Nat Commun 10 (1), 3226.
- 471 67. Snounou, G. and Pérignon, J.L. (2013) Malariotherapy--insanity at the service of
- 472 malariology. Adv Parasitol 81, 223-55.
- 473 68. Yorke, W., Macfie, J.W.S, Observations on malaria made during treatment of general
- 474 paralysis., Trans. R. Soc. Trop. Med. Hyg., 1924, pp. 13–44.

- 475 69. Yorke, W., On the malaria treatment of general paralysis of the insane., Lancet, 1926, pp.
- 476 427–431.
- 477 70. Boyd, M.F., Some characteristics of artificially induced vivax malaria., Am. J. Trop.Med,
- 478 1940, pp. 269–278.
- 479 71. Schmidt et al. (1982) The Characteristics of Untreated Sporozoite-Induced and
- Trophozoite-Induced Infections. Am J Trop Med Hyg 31 (3 (Pt 2)), 612-645.
- 481 72. Pinho, S. and Frenette, P.S. (2019) Haematopoietic stem cell activity and interactions
- with the niche. Nat Rev Mol Cell Biol 20 (5), 303-320.
- 483 73. Wickramasinghe, S.N. and Abdalla, S.H. (2000) Blood and bone marrow changes in
- 484 malaria. Baillieres Best Pract Res Clin Haematol 13 (2), 277-99.
- 485 74. Tang, Y. et al. (2017) Integrative analysis associates monocytes with insufficient
- 486 erythropoiesis during acute Plasmodium cynomolgi malaria in rhesus macaques. Malar J 16
- 487 (1), 384.
- 488 75. Moreno, A. et al. (2013) Plasmodium coatneyi in rhesus macaques replicates the
- multisystemic dysfunction of severe malaria in humans. Infect Immun 81 (6), 1889-904.
- 490 76. Lamikanra, A.A. et al. (2007) Malarial anemia: of mice and men. Blood 110 (1), 18-28.
- 491 77. Perkins, D.J. et al. (2011) Severe malarial anemia: innate immunity and pathogenesis. Int
- 492 J Biol Sci 7 (9), 1427-42.
- 493 78. Rodrigues-da-Silva, R.N. et al. (2014) Alterations in cytokines and haematological
- 494 parameters during the acute and convalescent phases of Plasmodium falciparum and
- 495 Plasmodium vivax infections. Mem Inst Oswaldo Cruz 109 (2), 154-62.
- 496 79. Lima-Junior, J.C. et al. (2012) Cells and mediators of inflammation (C-reactive protein,
- 497 nitric oxide, platelets and neutrophils) in the acute and convalescent phases of uncomplicated
- 498 Plasmodium vivax and Plasmodium falciparum infection. Mem Inst Oswaldo Cruz 107 (8),
- 499 1035-41.
- 80. Wilson, N.O. et al. (2010) Elevated levels of IL-10 and G-CSF associated with
- asymptomatic malaria in pregnant women. Infect Dis Obstet Gynecol 2010.
- 81. Mendonça, V.R. et al. (2013) Networking the host immune response in Plasmodium
- 503 vivax malaria. Malar J 12, 69.
- 82. Boiko, J.R. and Borghesi, L. (2012) Hematopoiesis sculpted by pathogens: Toll-like
- receptors and inflammatory mediators directly activate stem cells. Cytokine 57 (1), 1-8.
- 83. Chiba, Y. et al. (2018) Regulation of myelopoiesis by proinflammatory cytokines in
- infectious diseases. Cell Mol Life Sci 75 (8), 1363-1376.
- 84. Kovtonyuk, L.V. et al. (2016) Inflamm-Aging of Hematopoiesis, Hematopoietic Stem
- 509 Cells, and the Bone Marrow Microenvironment. Front Immunol 7, 502.
- 85. Belyaev, N.N. et al. (2010) Induction of an IL7-R(+)c-Kit(hi) myelolymphoid progenitor
- critically dependent on IFN-gamma signaling during acute malaria. Nat Immunol 11 (6), 477-
- 512 85.
- 86. Furusawa, J. et al. (2016) Promotion of Expansion and Differentiation of Hematopoietic
- 514 Stem Cells by Interleukin-27 into Myeloid Progenitors to Control Infection in Emergency
- 515 Myelopoiesis. PLoS Pathog 12 (3), e1005507.
- 87. Junqueira, C. et al. (2018) Cytotoxic CD8+ T cells recognize and kill Plasmodium vivax—
- infected reticulocytes. Nat Med 24 (9), 1330-1336.
- 88. Bain, B.J. (2005) Bone marrow biopsy morbidity: review of 2003. J Clin Pathol 58 (4),
- 519 406-8.

520521

### Box 1: BM aspiration in the clinical routine

BM biopsy is performed routinely as part of the clinical management of malaria patients with anaemia (Hb<7g/dl) to exclude other aetiologies, such as erythroid hyperplasia. The current knowledge gaps reported in this review are due, in part, to the fact that BM biopsy is often perceived as being associated with unnecessary risks for the patients and is therefore seldom performed on conscious individuals with mild illness. A study conducted in 2001-2003 and surveying about 20,000 BM aspiration/biopsy procedures across 63 hospitals reported only sixteen adverse events, representing 0.08% of total reported procedures and suggesting that risks are, in fact, minimal [88]. Larger studies with serial BM biopsies and/or aspirations from patients infected with *P. vivax* (pre/post treatment, for example) should therefore be considered in the future to shed more light on the BM "ecosystem" in vivax malaria.

Figure 1: *P. vivax* tissue distribution in non-human primates (NHPs). (A) Representative images obtained by Obaldia et al. [32] of parasites in the immunohistochemistry (IHC) analysis of bone marrow, liver, lung and brain. pLDH (total), PvLAP5 (gametocytes), and PvAMA1 (schizonts) antibodies were used to detect stage-specific parasites; CD31 antibodies stained the endothelium. Black arrowheads mark parasites. (B) Representative images obtained by Peterson et al. [34] of H&E-stained sections of bone marrow from a splenectomized animal and the spleen from the intact animal indicating the distribution of parasites (black arrows). (C-E) Heatmaps representing total, schizonts or gametocytes distributions in similar organs analyzed in 3 different studies: (C) Freemont et al. [33], (D) Obaldia et al. [32] and (E) Peterson et al. [34].

Figure 2: Comparison blood- and sporozoite-inoculation on experimental P. vivax infection dynamics. (A) Average parasitaemia curves of blood- (red line) and sporozoite-inoculated (blue line) P. vivax infections (St. Elizabeth strain) are highly similar for the first 1-2 months (solid lines) before they start to diverge, partially driven by relapses in sporozoite-inoculated individuals ( $N_{blood}=92$ ,  $N_{sporozoite}=88$ ). (B) Individual infection timeseries of P. vivax (St. Elizabeth strain) infected individuals, illustrating recurrent parasitaemias even in blood-inoculated infections (patient numbers S12 and S273, top and middle graph), especially following sub-curative drug treatment (arrows), and liver relapse following absence of peripheral parasites for  $\sim 2$  weeks (patient number S484, bottom graph). Data courtesy of G. M. Jeffery and W. E. Collins.

Figure 3, Key Figure: Potential *P. vivax*-induced immune responses in the bone marrow. Resident bone marrow cells, including hematopoietic stem cells (HSCs), multi-potent progenitors (MPPs) and endothelial cells express pathogen-recognition receptors (PRRs), such as Toll-like receptors (TLRs). This allows them to directly sense parasite-derived products presented by local antigen-presenting cells (APCs) or even infected immature reticulocytes, which still retain the capacity to present antigens via human leukocyte antigen class I. This would stimulate the release of cytokines such as IL-6 and G-CSF, which along with other cytokines that are produced during the course of infection, such as IL-1, IFNs and M-CSF, could act directly in the BM cells. This would promote HSC proliferation, myeloid-biased differentiation and also act in the granulocyte-monocyte progenitors (GMPs) and promote generation of myeloid cells.